Tirzepatide 5mg GIP GLP-1 RA CAS 2023788-19-2 Antidiabetic Medication Treatment

Tirzepatide

Basic Details:

 
 

 
 
Introduction:
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist originally developed by Lilly. Tirzepatide is a polypeptide drug composed of 39 amino acids, and its individual amino acids have undergone certain structural modifications.
In May of this year, Tilpoetide was approved by the US FDA as an auxiliary means of diet and exercise to improve blood sugar control in adults with type 2 diabetes, under the trade name Mounjaro. At present, the drug is not yet on the market in China and is in the registration application stage.
In addition to the hypoglycemic effect, Tirzepatide is particularly anticipated for its weight loss effect. In April this year, Eli Lilly announced that the global phase 3 clinical trial SURMOUNT-1 of Tirzepatide in the treatment of obesity or overweight groups had achieved positive results. After a period of 72 weeks After treatment, the average weight loss of the participants was up to 22.5% (24kg). Tirzepatide is the first drug to reduce the average body weight by more than 20% in phase 3 clinical trials so far.
Tirzepatide is available in six different doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) in prefilled single-dose auto-injectors for subcutaneous administration once weekly.
 
Mechanism Of Action:
It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.
 
Side Effects:
The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.